Author(s)

Serge Kouakou Kouassi^1*, Doumbia Moussa², Alexis Bahi³, Carole N’Guessan Djaman Obouayeba¹, Françis Adou Yapo¹, Joseph Allico Djaman^1,3

¹Biology and Health Laboratory, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire.
²Department of Bacteriology-Virology, Bacterial and Viral Serology Unit, Institut Pasteur of Côte d’Ivoire, Abidjan, Côte d’Ivoire.
³Department of Medical and Fundamental Biochemistry, Institut Pasteur of Côte d’Ivoire, Abidjan, Côte d’Ivoire.

Hepatitis C infection in people living with Human Immunodeficiency Virus (HIV) poses management challenges. Of the world’s population, 3% are estimated to have chronic Hepatitis C Virus (HCV) infection, which is responsible for about 70% of cases of chronic hepatitis (accelerated chronicity in the presence of HIV and for such major complications as cirrhosis and hepatocellular carcinoma. The fibrosis 4 (FIB-4) and Aspartate aminotransferase/platelet ratio index (APRI) scores are simple, inexpensive tests accessible to most people, and their performance has not yet been studied in C?te d’Ivoire. Objective: To prospectively evaluate the diagnostic performance of APRI and FIB-4 scores in liver damage in those co-infected with HIV/HCV in C?te d’Ivoire. Methods: This study was conducted over three months. The patients came from national blood transfusion center of the cities of Man and Daloa. The criteria for selecting respondents were at least 18 years of age and a positive test for HIV and HCV. APRI and FIB-4 scores were calculated for each patient from biological data obtained by COBAS C311 (Roche Hitachi, Japan). Statistical analyses were performed using GraphPad and MED-CALC software. Results: Our study involved 30 patients (men) of middle age (25 - 52 years), with extremes ranging from 0.67 to 8 for APRI and 0.201 to 22 for FIB-4. A predictive APRI and FIB4 score of significant hepatic fibrosis was observed in 23% of patients; however, 46% and 54% of patients for the APRI and FIB-4 score, respectively, would not have significant fibrosis. An APRI and FIB4 score not included in the classification limits of the type of fibrosis hepatitis was observed in 31% and 23% of patients, respectively. Conclusion: The performance of the APRI and FIB-4 biological scores analyzed according to the interpretation of their cut-off values would enable classifying about 70% and 77%, respectively, of the patient population in the stages of hepatitis C fibrosis.

Co-Infected Patients, HIV, HCV, APRI and FIB-4

Kouassi, S. , Moussa, D. , Bahi, A. , Obouayeba, C. , Yapo, F. and Djaman, J. (2023) Stratification of the Degree of Hepatic Involvement in HIV-HCV Coinfection Using Two Biomarkers: APRI and FIB-4. Journal of Biosciences and Medicines, 11, 60-70. doi: 10.4236/jbm.2023.118006.